-       Report 
   - November 2025
    -  274 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  50 Pages 
    Global
   
   From       €2382EUR$2,650USD£2,089GBP 
                      Erdosteine is a respiratory drug used to treat bronchitis, bronchial asthma, and other respiratory conditions. It is a mucolytic agent, meaning it helps to break down and thin mucus in the lungs, making it easier to cough up. It is available in tablet, syrup, and capsule form, and is often used in combination with other medications. Erdosteine is a relatively new drug, having been approved for use in Europe in the late 1990s.
The Erdosteine market is composed of a variety of pharmaceutical    companies, including GlaxoSmithKline, Sanofi, and Boehringer Ingelheim. These companies produce and distribute the drug in various countries around the world. Additionally, there are a number of generic manufacturers that produce Erdosteine in generic form. These companies are typically smaller, regional companies that specialize in generic drugs. 
Overall, the Erdosteine market is a growing one, with more and more companies entering the market each year. Companies such as GlaxoSmithKline, Sanofi, Boehringer Ingelheim, and generic manufacturers are all competing to provide the best quality product at the most competitive prices. Show Less   Read more